Brain tumor field enters new year with momentum after significant developments & progress in 2016.
National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community, enters 2017 with greater enthusiasm about its mission – to find better treatments and ultimately a cure for brain tumors – than ever before. A host of important advancements within the neuro-oncology and oncology fields during the past year, have set the stage for even greater progress in 2017. Many of these discoveries and advancements were accomplished as a result of NBTS research funding, public policy advocacy, and other activities.
In neuro-oncology, there has been encouraging news in the movement towards more precision-based medicine (tailoring treatment to the individual patient) and immunotherapeutic approaches in the past couple of years. Recent advances in the molecular analysis, understanding, and characterization of brain tumors – including the potential role cancer stem cells, epigenetics, tumor metabolism, and tumor microenvironment play in the initiation, progression, and maintenance of tumors – have created optimism that more effective and beneficial treatments are within reach. This includes a number of ongoing phase 3 clinical trials awaiting data and results in 2017 and 2018, as well as the publishing of long-term data confirming that adding Optune to temozolomide, following surgery and radiation, extends survival in newly diagnosed glioblastoma patients.
Below are 10 examples of key developments and discoveries in the field of neuro-oncology in 2016:
Click here to read the 10 examples and to see the full press release by National Brain Tumor Society.